Inactivated SARS-CoV-2 Vaccine Patent Granted Colorado State
Summary
The USPTO granted Patent US12605442B2 on April 21, 2026 to Colorado State University Research Foundation. The patent covers methods for inactivating viral particles using UV light and riboflavin, including SARS-CoV-2 particles, and vaccine compositions comprising inactivated viral particles with adjuvants capable of promoting a Th1-type immune response. Inventors are Raymond P. Goodrich and Richard Bowen.
What changed
USPTO granted Patent US12605442B2 for methods of inactivating viral particles using UV light in the presence of riboflavin, including SARS-CoV-2, and vaccine compositions comprising inactivated viral particles and adjuvants promoting Th1-type immune response. The patent names Raymond P. Goodrich and Richard Bowen as inventors and assigns rights to Colorado State University Research Foundation.
This is a routine patent grant event with no downstream compliance obligations. Pharmaceutical companies developing or licensing vaccine technologies may wish to review the patent claims for freedom-to-operate considerations.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Production of vaccines comprising inactivated SARS-CoV-2 viral particles
Grant US12605442B2 Kind: B2 Apr 21, 2026
Assignee
Colorado State University Research Foundation
Inventors
Raymond P. Goodrich, Richard Bowen
Abstract
Provided herein are methods for inactivating a viral particle, the methods comprising contacting the viral particle with UV light in the presence of riboflavin. In some embodiments, the viral particle is a SARS-CoV-2 particle. Vaccine compositions comprising inactivated viral particles (e.g., inactivated SARS-CoV-2 particles) are also provided. In some embodiments, the vaccine compositions comprise an adjuvant capable of promoting a Th1-type immune response.
CPC Classifications
A61K 39/215 A61K 39/39 A61K 2039/5252 A61K 2039/55561 A61K 2039/55566 A61K 2039/525 A61K 2039/5254 A61K 2039/54 A61K 2039/543 A61K 39/12 A61P 31/14 Y02A 50/30 A61M 2202/206 C12N 2770/20034
Filing Date
2021-03-05
Application No.
17905700
Claims
12
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.